HD Chromoendoscopy Coupled with DNA Mass Spectrometry Profiling Identifies Somatic Mutations in Microdissected Human Proximal Aberrant Crypt Foci

David A. Drew1,3, Thomas J. Devers2,3, Michael J. O’Brien4, Nicole A. Horelik1,3, Joel Levine2,3, and Daniel W. Rosenberg1,3

Abstract

Despite increased implementation of screening colonoscopy, interval cancers in the proximal colon remain a major public health concern. This fact underscores the limitations of current screening paradigms and the need for developing advanced endoscopic techniques. The density of aberrant crypt foci (ACF), the earliest identifiable mucosal abnormality, may serve as a surrogate marker for colon cancer risk, but has rarely been studied in the proximal colon. To this end, high-definition (HD) chromoendoscopy was conducted to define the relevance of ACF in the proximal colon. In addition, due to limited ACF size, the development of a combinatorial approach was required to maximize data acquisition obtained from individual biopsy samples. Proximal and distal ACF samples were characterized for a total of 105 mutations across 22 known tumor suppressor and proto-oncogenes using high-throughput Sequenom MassARRAY analysis. From this profiling, a discrete number of somatic mutations were identified, including APC(R876) and FLT3(I836M), as well as a deletion within the EGFR gene. Combined, these data highlight the significance of ACF within the context of colon cancer pathogenesis, particularly in the proximal colon.

Implications: The identification of cancer-related mutations in commonly overlooked mucosal lesions underscores the preventive benefit of implementing advanced endoscopic screening to larger patient populations, particularly in the proximal colon.

Visual Overview: http://mcr.aacrjournals.org/content/early/2014/05/22/1541-7786.MCR-13-0624/F1.large.jpg.

Introduction

Screening colonoscopy has been established as an effective strategy to reduce the risk of colorectal cancer (1). However, recent evidence suggests that protection may be most successful in the distal colorectum as the incidence of proximal colon cancer has not been significantly reduced by the implementation of widespread screening colonoscopy (2). The frequency of interval colon cancers, or those cancers developing between screening procedures, raises the possibility that proximal tumors in particular may have accelerated growth characteristics that limits the effectiveness of colonoscopy (3). This lack of protection afforded by colonoscopy, in particular within the proximal colon, underscores the need for advanced endoscopic techniques that may be used to identify small precursor lesions that would otherwise be missed by traditional screening approaches.

The multistage colon cancer model provides a paradigm for understanding the role of early mutations in cancer progression through defined histologic stages (4). Aberrant crypt foci (ACF) are morphologically identifiable mucosal abnormalities, a subset of which may be precancerous and contribute to a "field defect" within the mucosa (5). With the use of dye-spray (e.g., indigo carmine or methylene blue) and high-definition (HD) magnifying colonoscopy, the in situ identification of ACF has become relatively straightforward (6, 7). Although their utility as a surrogate marker of colon cancer has been challenged (8, 9), we recently reported that elevated numbers of distal ACF observed during index colonoscopy predicts the development of advanced neoplasia within a 5-year screening interval (10).

The following study was undertaken to more accurately define the molecular alterations that are present within colonic ACF. Using DNA mass spectrometry (DNA-MS)
Figure 1. Endoscopic detection of proximal ACF. A, HD magnifying colonoscopy combined with dye-spray reveals diminutive flat lesions of the proximal colorectum, including ACF and flat adenomas. B, frequency of ACF according to colonic location identified during screening chemoendoscopy. C, histologic appearance of normal colonic mucosa and ACF procured from the proximal colon. Proximal lesions display the same type of morphologies commonly associated with distal colon ACF, including dysplasia and hyperplasia (distended and serrated; ×200 magnification; bar, 60 μm).
combined with laser capture microdissection (LCM), we report a highly sensitive method to interrogate the mutational spectrum of microscopic biopsies following their removal from the human colon. A limited number of somatic mutations have been identified, including mutations to APC<sup>W876L</sup> and FLT3<sup>I836M</sup>, as well as an insertion/deletion within the EGFR gene, underscoring the biologic significance of ACF within the context of colorectal cancer and in particular within the proximal colon.

**Materials and Methods**

**Subject selection**

All subjects underwent a total screening colonoscopy at the University of Connecticut Health Center (UCHC) in accordance with the institutional policies. Patients who met the Amsterdam criteria for familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer (HNPCC) were excluded from the study. This study was performed only following the institutional review board approval and receipt of written informed consent from the subjects.

**ACF collection and characterization**

ACF were identified in situ and biopsied from grossly normal-appearing colonic mucosa during HD, close-focus magnifying chromoendoscopy. The proximal colon from the cecum to the right hepatic flexure, in addition to the distal 20-cm of the colorectum, were sprayed with a freshly prepared solution of 1% indigo carmine. ACF were visualized and photographed using a HD colonoscope (Olympus, PCF-190; Olympus Corp.) with visualization from 2 to 100 mm at ×60 magnification. A finding was accepted as an ACF if five or more crypts had an increased lumen diameter (1.5–2×), thick crypt walls, or abnormally shaped lumens relative to the surrounding mucosa. In addition, the lesion must be less than 5 mm in diameter to be considered an ACF. Biopsies were immediately embedded in freezing medium (OCT), flash frozen, and stored at −80°C.

Frozen sections were stained with hematoxylin and eosin (H&E) and routine histologic analyses were performed by two independent, board-certified human gastrointestinal pathologists blinded to clinical findings according to our previously established criteria (11). Dysplastic ACF are characterized

![Figure 2](https://www.aacrjournals.org/molcanres/article-pdf/12/6/825/5307959/molcanres-12-0624.pdf)

**Figure 2.** DNA-MS identifies FLT3<sup>I836M</sup> and a deletion to the EGFR gene in hyperplastic ACF. A, DNA-MS identification of an insertion/deletion to the EGFR gene in a serrated hyperplastic proximal colon ACF. B, DNA-MS detection of a G>C missense mutation resulting in FLT3<sup>I836M</sup> somatic mutation in a distended hyperplastic distal colon ACF. UEP, unextended primer.
Drew et al.

A

\[ \text{APC}^{R876*} \]

B

Adjacent normal mucosa

Dysplastic crypts

C

Dysplastic ACF

Tubular adenoma 1

Tubular adenoma 2

Tubular adenoma 3

Whole blood

UESP

APCR876*

No call(1)

T(8)  TQ(2)  C(15)  Other(1)
histologically by enlarged upper cryptal regions of irregular shape with stratified, elongated nuclei and a general dysplastic appearance. Hyperplastic ACF are characterized according to the same criteria applied to hyperplastic polyps (12). These hyperplastic ACF are subclassified into serrated and distended (non serrated) pathologies as previously described (11). Briefly, serrated ACF are defined as ACF that show stellate luminal shape upon cross-section with a prominent component of columnar crypts with microvesiccular cytoplasm. Distended ACF lack serration, prominently feature goblet cells, and frequently exhibit tufting of the surface epithelium.

**LCM and DNA purification**

A Veritas microdissector was used to capture approximately 5,000 cells (or the equivalent of approximately 1 mm² of collected tissue area) from 12-µm thick frozen serial sections of ACF prepared on PEN membrane glass slides (Applied Biosystems). Genomic DNA was extracted from aberrant crypts (isolated from surrounding stroma and normal mucosa by LCM) using the PicoPure DNA extraction kit (Applied Biosystems). Samples were then cleaned using the DNA Wizard protocol (Promega).

**Somatic mutation screening using DNA-MS**

Mutation screening was performed at the Yale Center for Genome Analysis using the Sequenom MassARRAY DNA-MS approach. This method uses a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) platform to detect single-base mutations with increased sensitivity (13). Extracted DNA was amplified using multiplexed OncoCarta PCR primers targeting 105 mutations across 22 known tumor suppressor and proto-oncogenes (v.3.0; Sequenom Inc.; Supplementary Table S1). The DNA concentration per reaction approached 1 ng of genomic DNA (Supplementary Fig. S1), a concentration that is within the limits of detection for the Sequenom platform (13). DNA-MS was carried out as previously described (13). Briefly, target regions are amplified through multiplex PCR reactions. Shrimp alkaline phosphatase is added to the reaction to dephosphorylate unincorporated dNTPs and an extension reaction mix is added. A post-PCR primer extension reaction creates a single-nucleotide extension using mass-modified terminators and the reactions are desalted using 6 mg of CLEAN Resin. Reaction products are then printed onto a SpectroCHIP to be read by MALDI-TOF MS. Mass spectrometry data are then analyzed using Typer4.0 software to identify sample genotype with respect to the assayed mutation.

Somatic mutations were confirmed by extracting DNA from whole blood using the DNAeasy Blood & Tissue Kit standard protocol (Qiagen) and sequenced by GENEWIZ, Inc. To determine mutation status in adenomas, DNA was extracted from two 10-µm FFPE curls using the QIAamp DNA FFPE Tissue Kit standard protocol and sequenced (GENEWIZ, Inc.) Primer sequences for PCR amplification and Sanger sequencing were: EGFR F: 5′-CCCCCCAGCAA-TATCAGCCCTTA-3′; R: 5′-ATAGAGTAGCTCCTGGGACC-3′; APC F: 5′-GGATGTCCTCAAGAACCTCATTCC-3′; R: 5′-TAGGGTCGCTGGTATTGAC-3′; FLT3 F: 5′-AGAACTCGACGCAACCATAACGC-3′; R: 5′-ACCCCTC-TGATCTGCCCCCTC-3′ (Integrated DNA Technologies). Sanger sequencing for BRAF and KRAS mutations was performed as previously described (14).

**Immunohistochemistry**

Immunohistochemistry (IHC) was performed on frozen tissue sections prepared at 7-µm thickness. Sections were treated with 3% hydrogen peroxide, blocked, and incubated in anti-β-catenin primary antibody (1:2,000; Sigma-Aldrich). Sections were incubated in ImmPRESS anti-mouse Ig (Vector Laboratories). Signal detection was achieved using a 3,3′-diaminobenzidine solution (Vector Laboratories) and tissues were counterstained with methyl green nuclear stain.

**Results and Discussion**

**HD chromoendoscopy positively identifies ACF in the proximal colon**

Using HD chromoendoscopy, we and others have previously demonstrated the ability to identify ACF within the distal colon (6, 7). We have recently expanded our analysis to include the identification of ACF within the proximal colon, a region of the colon that includes the cecum to the splenic flexure (Fig. 1A). A total of 96 patients have been screened and 88 proximal ACF and 1,010 distal ACF have been identified (Fig. 1B). The majority of the subjects were undergoing a screening colonoscopy (n = 70 of 96; 73%) and approximately half of the subjects (n = 47 of 96; 49%) had at least one polyp identified and removed during the procedure. Histologic evaluation reveals that proximal ACF harbor the full spectrum of established histologic abnormalities present within distal ACF, including hyperplasia (serrated or distended) and dysplasia (Fig. 1C).

ACF within the distal colon share many genetic and histologic abnormalities associated with more advanced colonic neoplasia. For example, hyperplastic ACF commonly harbor BRAF or KRAS mutations (14), resulting in increased ERK activation (11). The presence of ACF with dysplastic histologic features, however, is uncommon within the distal colon, although in one case a dysplastic ACF was found to carry a novel somatic mutation to the APC gene (14). A high frequency of APC mutations has been reported

---

Figure 3. DNA-MS reveals APC

Mutation screening was performed at the Yale Center for Genome Analysis using the Sequenom MassARRAY DNA-MS approach. This method uses a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) platform to detect single-base mutations with increased sensitivity (13). Extracted DNA was amplified using multiplexed OncoCarta PCR primers targeting 105 mutations across 22 known tumor suppressor and proto-oncogenes (v.3.0; Sequenom Inc.; Supplementary Table S1). The DNA concentration per reaction approached 1 ng of genomic DNA (Supplementary Fig. S1), a concentration that is within the limits of detection for the Sequenom platform (13). DNA-MS was carried out as previously described (13). Briefly, target regions are amplified through multiplex PCR reactions. Shrimp alkaline phosphatase is added to the reaction to dephosphorylate unincorporated dNTPs and an extension reaction mix is added. A post-PCR primer extension reaction creates a single-nucleotide extension using mass-modified terminators and the reactions are desalted using 6 mg of CLEAN Resin. Reaction products are then printed onto a SpectroCHIP to be read by MALDI-TOF MS. Mass spectrometry data are then analyzed using Typer4.0 software to identify sample genotype with respect to the assayed mutation.

Somatic mutations were confirmed by extracting DNA from whole blood using the DNAeasy Blood & Tissue Kit standard protocol (Qiagen) and sequenced by GENEWIZ, Inc. To determine mutation status in adenomas, DNA was extracted from two 10-µm FFPE curls using the QIAamp DNA FFPE Tissue Kit standard protocol and sequenced (GENEWIZ, Inc.) Primer sequences for PCR amplification and Sanger sequencing were: EGFR F: 5′-CCCCCCAGCAA-TATCAGCCCTTA-3′; R: 5′-ATAGAGTAGCTCCTGGGACC-3′; APC F: 5′-GGATGTCCTCAAGAACCTCATTCC-3′; R: 5′-TAGGGTCGCTGGTATTGAC-3′; FLT3 F: 5′-AGAACTCGACGCAACCATAACGC-3′; R: 5′-ACCCCTC-TGATCTGCCCCCTC-3′ (Integrated DNA Technologies). Sanger sequencing for BRAF and KRAS mutations was performed as previously described (14).

**Immunohistochemistry**

Immunohistochemistry (IHC) was performed on frozen tissue sections prepared at 7-µm thickness. Sections were treated with 3% hydrogen peroxide, blocked, and incubated in anti-β-catenin primary antibody (1:2,000; Sigma-Aldrich). Sections were incubated in ImmPRESS anti-mouse Ig (Vector Laboratories). Signal detection was achieved using a 3,3′-diaminobenzidine solution (Vector Laboratories) and tissues were counterstained with methyl green nuclear stain.

**Results and Discussion**

**HD chromoendoscopy positively identifies ACF in the proximal colon**

Using HD chromoendoscopy, we and others have previously demonstrated the ability to identify ACF within the distal colon (6, 7). We have recently expanded our analysis to include the identification of ACF within the proximal colon, a region of the colon that includes the cecum to the splenic flexure (Fig. 1A). A total of 96 patients have been screened and 88 proximal ACF and 1,010 distal ACF have been identified (Fig. 1B). The majority of the subjects were undergoing a screening colonoscopy (n = 70 of 96; 73%) and approximately half of the subjects (n = 47 of 96; 49%) had at least one polyp identified and removed during the procedure. Histologic evaluation reveals that proximal ACF harbor the full spectrum of established histologic abnormalities present within distal ACF, including hyperplasia (serrated or distended) and dysplasia (Fig. 1C).

ACF within the distal colon share many genetic and histologic abnormalities associated with more advanced colonic neoplasia. For example, hyperplastic ACF commonly harbor BRAF or KRAS mutations (14), resulting in increased ERK activation (11). The presence of ACF with dysplastic histologic features, however, is uncommon within the distal colon, although in one case a dysplastic ACF was found to carry a novel somatic mutation to the APC gene (14). A high frequency of APC mutations has been reported
previously in dysplastic ACF (15), but the inclusion of patients with FAP disease in this study may have exaggerated the prevalence of APC mutations. In an earlier study, we found that, a significant percentage of ACF (~40%) does not harbor mutations to BRAF or KRAS (11). Thus, in the present study, a broader genetic screen was undertaken to identify additional mutations that may contribute to early neoplastic changes in the colon.

**Application of DNA-MS for high-throughput genotyping of ACF**

Comprehensive mutation profiling of early neoplasia may provide insight into future colon cancer risk (16). However, there are a number of technical challenges associated with the application of high-throughput screening strategies to the analysis of small mucosal biopsy specimens. In addition, the number of morphologically abnormal colonic crypts within an ACF biopsy is limited, necessitating the use of LCM to enrich for subpopulations of aberrant and normal-appearing colonocytes. Recent advances in the DNA-MS technology using MALDI-TOF have provided a high-throughput, multiplexed approach to allow somatic mutational profiling with as little as 1 ng of input genomic DNA (13). To examine the feasibility of performing DNA-MS analyses on microdissected ACF samples, DNA was extracted from approximately 5,000 colonocytes and subjected to the MassARRAY PCR standard protocol. Amplification of genomic loci was achieved with less than 1 ng of input genomic DNA (Supplementary Fig. S1). A total of 26 microdissected ACF were then subjected to DNA-MS analyses. This group included seven proximal ACF, 19 distal ACF, and four normal colon biopsies.

As shown in Fig. 2A, a proximal, serrated hyperplastic ACF was positive for the in-frame insertion/deletion, c.2239_2251delTTAAAGAAGCAAAT(C, AAC, T, 747_751 > P), in the EGFR gene (19.6% deletion; 80.4% wild-type) as detected by MassARRAY. This mutation was not present in the subject’s blood, confirming that it was somatically acquired. Although EGFR mutations occur in approximately 6% of colorectal cancers (COSMIC; n = 3,102), they are much more frequent in lung adenocarcinomas (25.2%; COSMIC; n = 26,293). This specific mutation has not been previously detected in colorectal cancer and accounts for <1% of lung EGFR mutations, but is associated with a gain of EGFR function (17).

In addition, a distal, distended hyperplastic ACF was positive for a FLT3 c.2508C>G (I836M) mutation (24.0% mutant; 76.0% wild-type) and confirmed by Sanger sequencing to be somatic (Fig. 2B). FLT3 mutations have widely been implicated in cases of acute myeloid leukemia (23.5%; COSMIC; n = 63,213) and mutations to FLT3 occur in 4.8% of colorectal cancers (COSMIC; n = 1,003). To our knowledge, the c.2508C>G mutation found in this study has never before been reported in colorectal cancer. The I836M missense mutation has been shown previously to cause constitutive activation of the receptor tyrosine kinase and subsequent downstream signaling (18). Constitutive activation of these two receptor tyrosine kinases, not previ-
and we believe that in some cases this additional clinical effort is warranted. For example, the identification of the APC mutation, APC\(^{670G}\), associated with the formation of aggressive, invasive carcinomas (24) in a commonly missed mucosal lesion underscores the potential preventive benefit of implementing this clinical approach to larger patient populations. It is possible that ACF that harbor this and other significant somatic mutations have the capacity to rapidly progress to a more advanced neoplasia, perhaps representing a subset of "missed lesions" that may be responsible for interval colon cancers. Expanded molecular classification of proximal ACF with a DNA-MS panel designed specifically for colorectal cancer, as well as establishing detailed associations of proximal ACF with known colorectal cancer risk factors, will be necessary to firmly establish their premalignant potential and utility as a surrogate marker for future cancer risk.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References


www.aacrjournals.org Mol Cancer Res; 12(6) June 2014 829

Authors' Contributions
Conception and design: D.A. Drew, D.W. Rosenberg
Development of methodology: D.A. Drew, D.W. Rosenberg
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D.A. Drew, T.J. Devers, M.J. O’Brien, N.A. Horelik, J. Levine, D.W. Rosenberg
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D.A. Drew, T.J. Devers, D.W. Rosenberg
Writing, review, and/or revision of the manuscript: D.A. Drew, T.J. Devers, D.W. Rosenberg
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D.A. Drew, N.A. Horelik, D.W. Rosenberg
Study supervision: T.J. Devers

Acknowledgments
The authors thank Dr. T.V. Rajan for providing a detailed pathologic analysis of ACF. The authors also thank Dr. Shi Yang at Boston Medical Center for performing KRAS and BRAF sequencing services.

Grant Support
This work was supported by the State of Connecticut Department of Public Health, Biomedical Research Application #2012.0913 (to D.W. Rosenberg) and the NIH 1RO1CA159976 (to D.W. Rosenberg).

Received November 22, 2013; revised February 10, 2014; accepted February 25, 2014; published OnlineFirst March 20, 2014.

Published OnlineFirst March 20, 2014; DOI: 10.1158/1541-7786.MCR-13-0624

Downloaded from mcr.aacrjournals.org on June 13, 2021. © 2014 American Association for Cancer Research.